Saint Luke's University Hospital-Bethlehem Campus

Summary

Saint Luke's University Hospital-Bethlehem Campus is a medical facility located in Bethlehem, Pennsylvania. This center is recognized for care of Melanoma, Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreatic Cancer and other specialties. Saint Luke's University Hospital-Bethlehem Campus is involved with conducting 209 clinical trials across 328 conditions. There are 19 research doctors associated with this hospital, such as Melissa A. Wilson, Neil D. Belman, Darius Desai, and Gary Lu.

Top PIs

Clinical Trials running at Saint Luke's University Hospital-Bethlehem Campus

Ovarian Cancer

Lung Cancer

Breast Cancer

Pancreatic Cancer

Fallopian Tube Cancer

Uterine Cancer

Peritoneal Cancer

Heart Attack

Breast cancer

Brain Tumor

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Trastuzumab Deruxtecan + Bevacizumab

for Ovarian Cancer

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

Recruiting

2 awards

Phase 3

5 criteria

Rina-S

for Ovarian Cancer

This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.

Recruiting

2 awards

Phase 3

4 criteria